home / stock / umrx / umrx quote
Last: | $2.35 |
---|---|
Change Percent: | 0.43% |
Open: | $2.38 |
Close: | $2.35 |
High: | $2.41 |
Low: | $2.3201 |
Volume: | 124,651 |
Last Trade Date Time: | 10/05/2020 04:45:26 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.35 | $2.38 | $2.35 | $2.41 | $2.3201 | 124,651 | 10-05-2020 |
$2.34 | $2.37 | $2.34 | $2.4 | $2.26 | 389,011 | 10-02-2020 |
$2.26 | $2.3 | $2.26 | $2.37 | $2.22 | 160,246 | 10-01-2020 |
$2.34 | $2.25 | $2.34 | $2.401 | $2.25 | 207,492 | 09-30-2020 |
$2.25 | $2.28 | $2.25 | $2.37 | $2.21 | 307,265 | 09-29-2020 |
$2.28 | $2.31 | $2.28 | $2.38 | $2.2 | 241,357 | 09-25-2020 |
$2.31 | $2.46 | $2.31 | $2.55 | $2.26 | 334,918 | 09-24-2020 |
$2.5 | $2.66 | $2.5 | $2.69 | $2.46 | 288,942 | 09-23-2020 |
$2.74 | $2.86 | $2.74 | $2.94 | $2.5 | 518,629 | 09-22-2020 |
$2.85 | $2.98 | $2.85 | $3 | $2.76 | 170,023 | 09-21-2020 |
$2.94 | $2.86 | $2.94 | $3.05 | $2.78 | 787,786 | 09-18-2020 |
$2.86 | $2.89 | $2.86 | $2.99 | $2.7932 | 899,414 | 09-17-2020 |
$2.83 | $2.68 | $2.83 | $2.95 | $2.67 | 651,849 | 09-16-2020 |
$2.73 | $2.83 | $2.73 | $2.84 | $2.67 | 459,967 | 09-15-2020 |
$2.7 | $2.34 | $2.7 | $2.75 | $2.34 | 494,782 | 09-14-2020 |
$2.39 | $2.4 | $2.39 | $2.4949 | $2.3 | 236,797 | 09-11-2020 |
$2.42 | $2.41 | $2.42 | $2.52 | $2.35 | 407,320 | 09-10-2020 |
$2.41 | $2.26 | $2.41 | $2.469 | $2.245 | 364,155 | 09-09-2020 |
$2.29 | $2.32 | $2.29 | $2.32 | $2.17 | 367,315 | 09-08-2020 |
$2.2 | $2.17 | $2.2 | $2.31 | $2.05 | 320,405 | 09-07-2020 |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...